News

Learn how and why East Indian Sandalwood Oil (EISO) is making international headlines as a unique, non-substitutable botanical drug candidate.

Santalis Pharmaceuticals Announces Issuance of Patent for the Use of Sandalwood Oil to Treat Cancers

Posted on

SAN ANTONIO–(MEDIA)–Santalis Pharmaceuticals, Inc. announced today the issuance by the Japanese Patent Office of a patent that covers sandalwood oil-containing compositions that can be used to treat a variety of cancers. The patent for invention number 5,972,797 includes claims that protect compositions for treatment of solid tumors, including bladder cancer, and also covers preventing the progression of actinic keratoses (AK) […]Read More Santalis Pharmaceuticals Announces Issuance of Patent for the Use of Sandalwood Oil to Treat Cancers

Santalis Pharmaceuticals Initiates a Phase 2 Study of Mild, Moderate and Severe Atopic Dermatitis – Enrolls First Patient Into Its Australian Clinical Trial Site

Posted on

SAN ANTONIO–(MEDIA)–Santalis¬†Pharmaceuticals¬†today announced it has enrolled its first patient into a single-center, placebo-controlled, double-blinded, safety, efficacy and tolerability study using a unique 5% East Indian Sandalwood Oil (EISO) cream formulation for the treatment of atopic dermatitis (AD), also known as eczema. Patients will be 3 months to 65 years of age with a clinically stable diagnosis of atopic dermatitis with […]Read More Santalis Pharmaceuticals Initiates a Phase 2 Study of Mild, Moderate and Severe Atopic Dermatitis – Enrolls First Patient Into Its Australian Clinical Trial Site